CMS Proposes 6.4% Home Health Cut — Three Operators Most at Risk
The Centers for Medicare & Medicaid Services (CMS) has proposed a 6.4% aggregate payment reduction for home health agencies in calendar year 2026, part of its ongoing behavioral adjustment clawback under the Patient-Driven Groupings Model (PDGM). If finalized, the cut would represent one of the largest single-year rate reductions in the sector's history — landing at a moment when home health operators are finally emerging from years of margin compression and labor shortages.
Three publicly traded operators face the most direct exposure: Aveanna Healthcare (AVAH), Amedisys (AMED, now part of Optum/UnitedHealth), and The Ensign Group (ENSG). Each carries a different risk profile depending on payer mix, leverage, and strategic positioning.
What CMS Is Proposing
The proposed CY2026 Home Health Prospective Payment System rule includes a permanent behavioral adjustment of -4.067% layered on top of additional case-mix recalibrations, resulting in an estimated -6.4% net payment impact for Medicare-certified home health agencies. CMS argues that coding intensity and case-mix changes under PDGM have inflated payments beyond intended levels since the model's 2020 implementation.
The final rule is expected by late 2026. Industry groups including the National Association for Home Care & Hospice (NAHC) and the Partnership for Quality Home Healthcare have pushed back aggressively, arguing the cuts could force agency closures in rural and underserved markets.
Aveanna Healthcare (AVAH): Highest Financial Risk
Why it matters most here: Aveanna is the most leveraged operator in the group, with debt-to-equity at 135.7x and debt-to-EBITDA at 5.1x as of the latest quarter. The company carries approximately $1.35 billion in total debt against a market capitalization of just $1.47 billion.
Aveanna has been on a strong operational recovery trajectory. Revenue grew 22.2% year-over-year in Q3 2025 to $622 million, and the company raised 2025 guidance three times — targeting revenue above $2.375 billion and adjusted EBITDA above $300 million. The episodic home health segment, where Medicare reimbursement is most relevant, saw 14.2% volume growth in Q3 with episodic mix at 77%.
But this recovery is fragile. Operating margins remain thin at 10.2% TTM, and interest coverage sits at just 1.6x. Management explicitly flagged the proposed CMS home health rule as a risk on both the Q2 and Q3 2025 earnings calls, noting "uncertainty around the proposed Medicare home health rule for 2026 and its potential cuts to home health benefits."
| Metric | AVAH |
|---|---|
| TTM Revenue | ~$2.3B |
| Q3 2025 Revenue | $622M (+22% YoY) |
| Operating Margin (TTM) | 10.2% |
| Debt / EBITDA | 5.1x |
| Interest Coverage | 1.6x |
| Total Debt | $1.35B |
| Market Cap | $1.47B |
Risk assessment: A 6.4% Medicare home health payment reduction applied to Aveanna's episodic home health revenue could translate to a $30-50 million annual EBITDA headwind, depending on the proportion of Medicare episodic revenue. For a company guiding to ~$300 million in adjusted EBITDA, that represents a 10-17% hit — significant given the thin margin of safety on debt covenants. Aveanna's stock has already declined 22% over three months and 13% year-to-date, suggesting the market is partially pricing in regulatory risk.
Amedisys (AMED): Absorbed Into Optum
Amedisys, once the second-largest home health provider in the U.S., completed its merger with Optum (a UnitedHealth Group subsidiary) in 2024. AMED no longer trades publicly, and its home health operations are now embedded within Optum Health's care delivery segment.
While the CMS cut would still affect Amedisys's underlying operations, the financial impact is now absorbed by UnitedHealth Group's $370+ billion revenue base. The strategic relevance shifts: UnitedHealth may use Amedisys's scale to negotiate managed care rates that offset Medicare reductions — a luxury standalone operators don't have. For investors tracking home health exposure through UNH, the CMS proposal is a marginal headwind rather than an existential threat.
The Ensign Group (ENSG): Best Positioned to Absorb
Ensign is primarily a skilled nursing facility (SNF) operator, but its growing home health and hospice segment creates exposure to the CMS proposal. The key difference: home health represents a smaller share of Ensign's $5.06 billion revenue base (FY2025), and the company's financial profile provides substantial cushion.
| Metric | ENSG |
|---|---|
| FY2025 Revenue | $5.06B (+18.7% YoY) |
| FY2025 EBITDA | $568M |
| Operating Margin (TTM) | 8.4% |
| Debt / Equity | 1.86x |
| EV / EBITDA | 27.8x |
| Market Cap | $12.2B |
| 2026 EPS Guidance | $7.41 - $7.61 |
Ensign's Q4 2025 earnings call projected 14.3% EPS growth for 2026 with revenue guidance of $5.77-$5.84 billion. Management highlighted that skilled nursing was carved out of provider tax reductions in the reconciliation bill — a regulatory win that doesn't apply to home health but signals Ensign's political awareness. Same-store occupancy hit all-time highs of 83.8%, and the acquisition pipeline remains active with 17 new operations added in Q4 alone.
Risk assessment: Given that Ensign's home health revenue is a fraction of its SNF-dominated portfolio, the CMS home health cut would likely have a low single-digit percentage impact on consolidated EBITDA. The company's diversified revenue streams, low interest costs ($2M/quarter), and robust acquisition-driven growth model provide a wide buffer.
Investment Implications
The Bull Case
- The proposed rule is not final. Industry lobbying has historically softened CMS cuts — the CY2025 rule was moderated after public comment. Operators with strong advocacy presence (Aveanna is active through NAHC) could see a reduced final rate.
- Home health volume demand is structurally growing as the population ages and payers shift toward lower-cost care settings. Even with rate cuts, volume growth may offset per-episode reductions.
The Bear Case
- CMS has been consistent in applying behavioral adjustments since PDGM's 2020 launch. The 6.4% is cumulative policy, not a one-time surprise — and further adjustments could follow in CY2027.
- For highly leveraged operators like Aveanna, even a partial implementation could pressure debt covenants and limit strategic flexibility at a time when the company is pursuing acquisitions (Family First Homecare announced March 12, 2026).
What to Watch
- Final rule publication (expected late 2026): The delta between proposed -6.4% and the final number will be the single most important catalyst.
- Aveanna Q4 2025 earnings (March 19, 2026): Management commentary on CMS mitigation strategies and updated 2026 guidance.
- Congressional action: Any legislative fix to limit CMS behavioral adjustments would be a significant positive for the sector.
- Ensign's home health segment disclosure: Watch for breakout reporting that quantifies home health exposure as a percentage of revenue.
Sources: CMS CY2026 Home Health Proposed Rule, company earnings calls (AVAH Q2-Q3 2025, ENSG Q1-Q4 2025), SEC filings, company press releases.